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There are few evidence-based guidelines to inform optimal design of complex clinical trials, such as
those assessing the safety and efﬁcacy of intravenous drugs administered daily with infusion times over
many hours per day and treatment durations that may span years. This study is a retrospective review of
inpatient administration deviation reports for an investigational drug that is administered daily with
infusion times of 8e24 h, and variable treatment durations for each patient. We report study design
modiﬁcations made in 2007e2008 aimed at minimizing deviations from an investigational drug infusion
protocol approved by an institutional review board and the United States Food and Drug Administration.
Modiﬁcations were speciﬁcally aimed at minimizing errors of infusion rate, incorrect dose, incorrect
patient, or wrong drug administered. We found that the rate of these types of administration errors of
the study drug was signiﬁcantly decreased following adoption of the speciﬁc study design changes. This
report provides guidance in the design of clinical trials testing the safety and efﬁcacy of study drugs
administered via intravenous infusion in an inpatient setting so as to minimize drug administration
protocol deviations and optimize patient safety.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Clinical trials conducted in the United States investigating the
efﬁcacy and safety of a new drug or a new indication for an
approved drug are strictly regulated by institutional review boards
(IRBs) and are heavily scrutinized by the United States Food and
Drug Administration (FDA). The integrity and durability of any
clinical trial, and the preservation of patient safety, depend on
adherence to carefully considered, reviewed, and approved pro-
tocols for investigational drug administration. However, clinical
studies with complex components are susceptible to protocol de-
viations. For example, study drugs administered in the inpatient
setting that are not limited to patients treated by a particular
medical service or inpatient ward are susceptible to administration
errors due to lack of familiarity with the study protocol. Study drugsu (M. Puder).
Inc. This is an open access article uwith non-standard administration procedures, such as infusion
times and treatment durations that vary for each patient, are also
susceptible to administration errors.
Prior work characterizing the scope of problems related to the
administration of commonly prescribed intravenous drugs has
demonstrated that administration errors are not uncommon oc-
currences [1]. Clinical trials that include elements of complexity in
study drug administration protocols can be at increased vulnera-
bility to administration deviations. For such studies, achieving
adequate education and oversight to guarantee correct study drug
administration can present unique challenges. This study describes
a multi-modal strategy of modiﬁcations that reduced administra-
tion errors in a clinical trial involving daily use of an investigational
parenteral medication at a pediatric teaching hospital.
Omegaven® (Fresenius Kabi, Bad Homburg, Germany) is a ﬁsh
oil-based intravenous lipid emulsion. In the United States, Ome-
gaven® is not approved by the FDA for use as a fat source in
parenteral nutrition (PN). In 2004, a single-center study was initi-
ated by investigators at Boston Children’s Hospital (BCH) through ander the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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efﬁcacy and safety of this study drug in the treatment of parenteral
nutrition-associated liver disease (PNALD) in the pediatric popu-
lation [2,3]. PNALD is characterized by hepatic inﬂammation and
cholestasis that can progress to hepatic ﬁbrosis, cirrhosis, and end-
stage liver disease requiring liver transplantation. The design of this
study allows for any PN-dependent patient who develops chole-
stasis, deﬁned as a sustained direct bilirubin >2 mg/dL, with no
other diagnosis of liver disease, to receive the study drug, regard-
less of which medical or surgical service is caring for the patient.
The study drug is administered daily over an infusion time of at
least 8 h. In 2007, in response to observations by the BCH IRB that
inpatient protocol deviations were commonly the result of
administration errors, the principal investigators of the study and
hospital staff who participated in the care of study patients per-
formed a root-cause analysis of the errors. This resulted in a series
of protocol amendments and educational efforts aimed at mini-
mizing these errors. Changes focused on specifying a subset of
personnel to administer the study drug to inpatients and providing
specialized training, as well as adopting systems-level
modiﬁcations.
The purpose of this study is to describe and assess the effec-
tiveness of these initiatives aimed at reducing inpatient infusion
errors of an investigational medication and to provide guidance for
research groups designing similar clinical trials.2. Methods
2.1. Data collection
Safety Event Reporting System (SERS) reports of protocol de-
viations associated with administration of the study drug submit-
ted to the BCH IRB from 1/1/2005e12/31/2014 were retrospectively
reviewed. SERS reports included in this study were limited to those
detailing inpatient administration errors of incorrect dose, incor-
rect infusion rate, wrong drug infused, and incorrect patient
receiving the drug. An incorrect dose was deﬁned as at least a 20%
difference between what was administered and the prescribed
dose. This category included missed doses of the study drug. An
incorrect rate was deﬁned as an infusion rate that was at least
0.15 g/kg/hr different from the prescribed rate infused over at least
10 min. Errors of incorrect drug were events in which a patient
prescribed the study drug was administered another drug instead
of the study drug. Errors of incorrect patient were instances in
which a patient received study drug that was intended for another
patient, regardless of whether the patient receiving the study drug
was enrolled in the study.
Inpatient pharmacy records from Boston Children’s Hospital
were reviewed to determine the total number of inpatient doses of
the study drug administered annually from 2005 through 2014.
Annual administration errors and total annual doses administered
were used to calculate the annual rate of study drug inpatient
administration errors for each year from 2005 to 2014.
To capture the type of interventions performed, the 2007 Report
of Improvement submitted to the BCH IRB by the study’s principal
investigators was reviewed. This report detailed system changes
undertaken in 2007e2008 to minimize inpatient administration
errors of the study drug. These modiﬁcations particularly targeted
errors of incorrect dose, infusion rate, patient, and drug. Inpatient
administration error rates for the study drug from 2005 to 2008
were compared to those from 2009 to 2014 in order to evaluate the
efﬁcacy of the modiﬁcations adopted in minimizing inpatient
administration protocol deviations and maximizing the safety of
patients receiving the study drug infusion.2.2. Statistical analysis
The annual rate of study drug administration errors was calcu-
lated as the number of errors divided by the total number of
inpatient doses administered. Exact Poisson regression was used to
compare the error rate from 2005 to 2008 to the error rate from
2009 to 2014, via a generalized linear model with a logarithmic link
function. An offset variable, deﬁned as the natural logarithm of the
number of doses administered in a given year, was used to account
for different total study drug doses administered each year. There
was no evidence of overdispersion as determined by the scaling
parameter (deviance/df ¼ 0.998), and a sensitivity analysis with
negative binomial regression yielded results consistent with Pois-
son regression [4]. Point estimates of error rates, as well as for the
percent reduction in error rates from 2005 to 2008 to 2009e2014,
are provided with 95% conﬁdence intervals (CI). Statistical analysis
was performed with SAS version 9.3 (Cary, NC).2.3. Protocol design changes initiated to minimize infusion
administration deviations
Table 1 describes the study design improvements initiated over
2007e2008 aimed at minimizing study drug infusion administra-
tion errors. There were 3 categories of study design improvement:
personnel, training, and systems.
Changes to the study personnel structure included hiring a
dedicated research nurse for the study. This research nurse acts as a
resource for inpatient nurses and staff who care for patients
receiving the study drug but who may not be familiar with the
process of administering an investigational drug and the particular
study protocol. Use of the study drug was limited to speciﬁc inpa-
tient units in the hospital to allow the cohort of staff working on
those units to become familiar with the study drug and the protocol
for its administration. Additionally, to ensure only those most
familiar with the study protocol administer the drug, administra-
tion privileges were limited to nurses at the study institution who
consistently work on the units where the study drug was
administered.
Several formal training platforms were introduced, including
mandatory electronic learning modules for nurses who administer
the study drug followed by competency testing to assess under-
standing of the protocol requirements. Copies of the study protocol
were placed centrally on each inpatient ward for reference, and the
clinical trial staff met with inpatient caretakers to provide teaching
and clariﬁcations about the protocol. Nurses caring for study pa-
tients were required to review protocol material and undergo
competency testing annually.
System improvements were established to differentiate the
study drug from other, identical-appearing lipid emulsions and to
utilize electronic point of care medication administration (bar
coding) to render it more difﬁcult to commit an error in the
administration process. Steps to make the study drug more
recognizable included using uniquely colored bags for delivering
the study drug from the pharmacy to inpatient units, enlarging the
auxiliary label denoting the drug as investigational, and storing the
study drug separately from other intravenously infused substances
on each inpatient ward. At the time of administration, a mandatory
double check of the infusion pump by two independent personnel
was adopted to ensure the correct pump settings and correct source
container connection. To prevent wrong patient and wrong drug
errors, two independent methods of patient identiﬁcation prior to
initiation of each infusion and prior to any change in infusion rate
was adopted to ensure the correct patient received each dose of
study drug.
Table 1
Improvements initiated in 2007e2008.
Personnel
Dedicated research nurse
Only full-time nurses at study institution may administer study drug
Limit use of the study drug to a few units in the hospital
Training
Mandatory electronic learning module
Competency testing
Information/Protocol binder on each ward
Mandatory staff meetings with nurse managers and nurses
Annual review of protocol material and testing
Systems
Electronic point of care medication administration (bar coding)
Different color delivery bags for study drug
Make “Investigational” label of study drug more obvious
Store study drug separately from other intravenous ﬂuids
Double check pump after initiating study drug
Two methods of patient identiﬁcation Fig. 1. Average annual rate of Omegaven administration errors. Shown are mean (95%
conﬁdence interval) and P value from exact Poisson regression for the time periods
2005e2008 (prior to initiation of improvement strategies) and 2009e2014 (after
adoption of improvement strategies).
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3.1. Study drug administration error rates decreased with
improvement initiatives
Table 2 shows the number of study drug administration de-
viations of incorrect dose, incorrect infusion rate, incorrect patient,
and incorrect drug for each year included in the study. The average
annual error rate for the time period prior to the adoption of study
improvements (2005e2008) was 0.35%. Following the adoption of
improvements from 2009 to 2014, the average annual error rate
was decreased (P ¼ 0.003) to 0.14% (Fig. 1). This represents a 60%
(95% CI: 25e79%) reduction in the error rate from 2005 to 2008
after accounting for a 9% decrease in the rate of administered doses
over 2009e2014.
4. Discussion
Here we demonstrate changes in clinical research protocol
design that successfully decreased the number of inpatient infusion
errors of a study drug. These interventions included limiting
personnel and inpatient units allowed to administer the study drug,
specialized training to educate inpatient caregivers about the pro-
tocol and speciﬁc study drug requirements, and systems improve-
ments aimed at making it easier to differentiate the study drug
from other similar drugs andmore difﬁcult to administer thewrong
drug or to the incorrect patient. Additionally, these protocol mod-
iﬁcations effectively heightened awareness among staff of the need
and rationale for strict adherence to the research protocol of an
investigational drug.
The infusion error rate in this study prior to the adoption of the
changes was low, at 0.35% annually, compared to published error
rates of infused medications which are reported as 5%e30% [5e7].
Although the infusion error rate in this study was low prior toTable 2
Annual study drug administration deviations.
Administration errors 2005e2008
2005 2006 2007 2008 Total Mean/yr
Total inpatient doses 1013 1478 2784 3623 8898 2224.5
Error: wrong dose 2 2 6 4 14 3.50
Error: wrong rate 0 4 3 4 11 2.75
Error: wrong drug 0 0 0 2 2 0.50
Error: wrong patient 0 1 3 0 4 1.00
Total errors 2 7 12 10 31
Error rate 0.20 0.47 0.43 0.28 0.35adoption of the changes, standards for administration of investi-
gational drugs are more rigorous than the standard of care, and for
maximization of patient safety and study integrity the goal in
clinical trials is to achieve an error rate as close to zero as possible. A
statistically and clinically signiﬁcant step toward attaining a near
zero error rate was achieved through initiation of these changes in
the study design.
Efforts to understand the etiology of medication administration
errors have been undertaken previously. Several groups have
identiﬁed interruptions in the medication veriﬁcation process as
highly associated with medication administration error rates [8],
and others have attempted to deﬁne strategies to reduce errors
related to interruptions in drug veriﬁcation and administration [9].
Elements of the study design changes in this study, including a
mandatory independent double-check of the pump settings to
ensure correct infusion rate, requiring two modes of patient iden-
tiﬁcation, have promoted increased awareness in the veriﬁcation
and administration processes. Although inquiry into the speciﬁc
etiologies of medication administration errors is beyond the scope
of this report, the fact that interventions aimed at minimizing the
impact of disruptions or distractions in drug and patient veriﬁca-
tion support the idea that these factors may contribute to admin-
istration errors.
Reports have been published providing guidance for minimizing
errors in the administration of chemotherapeutic agents, which are
often part of oncologic research protocols. The American Society of
Health-System Pharmacists published guidelines in 2015 for
maximizing the safety of chemotherapy infusions, including
specialized training for personnel administering chemotherapy,
open access to the study protocols of their patients, and the use of
bar coding and checklists to avoid infusion errors [10]. Chemo-
therapy infusions typically take place in specialized inpatient unitsAdministration errors 2009e2014
2009 2010 2011 2012 2013 2014 Total Mean/yr
1838 2451 1828 1557 2516 1999 12189 2031.5
1 0 2 1 1 1 6 1.00
3 1 1 2 3 0 10 1.67
0 0 0 0 0 0 0 0.00
0 0 0 0 1 0 1 0.17
4 1 3 3 5 1 17
0.22 0.04 0.16 0.19 0.20 0.05 0.14
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patients. Furthermore, chemotherapy protocols include ﬁxed du-
rations of therapy. PN-dependent patients who develop PNALD and
meet criteria to receive the study drug in this report may be treated
by any of several care teams on nearly any inpatient unit in the
hospital. Furthermore, the duration of PN-dependence and need for
the study drug are different for each patient enrolled in the study.
As part of the improvement strategy reported here, steps were
taken to limit the nursing staff who may administer the study drug,
incorporate training, and place the study protocol on each inpatient
unit where the study drug was administered to minimize admin-
istration errors.
Studies in the anesthesiology ﬁeld have reported systems-level
measures to reduce medication administration errors in the oper-
ating room. Thesemeasures include improved labeling of drugs and
use of color-coded systems to make drug identiﬁcation and veriﬁ-
cation easier, use of pre-ﬁlled syringes, and use of barcoding sys-
tems to improve medication administration records [11,12]. In this
report, similar improvements in labeling, storage, and use of elec-
tronic bar codes for the investigational drug were all strategies that
contributed to minimizing administration errors.
Several studies exist that investigate methods to reduce
medication administration errors in other settings, however, re-
sults are inconsistent and overall evidence for the effectiveness of
any single intervention remains questionable. A meta-analysis of
10 studies aimed at reducing interruptions of nurses during
medication administration reported mixed effectiveness of efforts
to reduce interruptions [13]. Of the 10 studies included, only three
reported the effect of administration interruption on medication
administration errors, however all three reported reductions in
errors after intervention to decrease interruptions. Two of the 3
showed signiﬁcant reductions in percentage of administrations
with errors from 16.6% to 2% over 12 months and 14.6%e4.2% over
18 months. The third study had a low pre-intervention percentage
of administrations with errors at 2%, which was reduced to 0% at 6
months following intervention. A second meta-analysis of 24
studies investigated methods to reduce medication errors in adult
ICU patients. This study included mostly pre- and post-
intervention observational comparison studies, and two prospec-
tive randomized controlled trials. This study reported mixed re-
sults for a variety of interventions that included computerized
physician order entry, changes in work schedule, medication
reconciliation, automated intravenous pump systems, modes of
education, pharmacist involvement, protocols and guidelines, and
support systems for clinical decision-making [14]. Of the two
prospective randomized controlled trials included, one focused
only on changes in intern work hours and reported small re-
ductions in medication errors committed by interns with reduced
work hours. The other focused on the effect of automated infusion
pump systems, and found no signiﬁcant improvement in errors
with use of such systems.
Our study is an observational pre- and post-intervention
comparison of a multi-modal approach aimed at decreasing
administration deviations of a study drug. While a prospective
randomized-controlled trial would have been ideal for investi-
gating the impact of new interventions to decrease administration
errors, such a design was not possible in this study as the inter-
vention strategies were developed and implemented at the
request of the Institutional Review Board and required for all pa-
tients enrolled in the study. Furthermore, in utilizing a multi-
modal approach, it was not possible to conclude which strategies
had the greatest impact on administration deviations because all
measures were initiated within a short period as part of a
comprehensive strategy to reduce administration deviations of the
study drug.5. Conclusions
Based on these results, we recommend a multifactorial
approach that integrates use of a dedicated study nurse, limiting
the personnel allowed to administer the study drug and inpatient
units where the drug may be administered, educational initiatives
to train personnel in protocol requirements, mandatory medication
and patient veriﬁcation procedures, and use of labeling, color
coding, and electronic bar codes that make it easier to differentiate
the study drug from other drugs. These represent experience-based
guidelines meant to provide investigators with tools for developing
optimal protocols for clinical trials of intravenously infused drugs
that include strategies for minimizing administration deviations
and optimizing patient safety.
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